- Home
- WCT vs HOOK Comparison
WCT vs HOOK Comparison
Compare WCT & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WCT
- HOOK
- Stock Information
- Founded
- WCT 2012
- HOOK 2011
- Country
- WCT Hong Kong
- HOOK United States
- Employees
- WCT 7
- HOOK N/A
- Industry
- WCT
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- WCT
- HOOK Health Care
- Exchange
- WCT NYSE
- HOOK Nasdaq
- Market Cap
- WCT 9.7M
- HOOK 9.3M
- IPO Year
- WCT 2024
- HOOK 2019
- Fundamental
- Price
- WCT $0.18
- HOOK $1.25
- Analyst Decision
- WCT
- HOOK Buy
- Analyst Count
- WCT 0
- HOOK 4
- Target Price
- WCT N/A
- HOOK $10.67
- AVG Volume (30 Days)
- WCT 513.3K
- HOOK 62.9K
- Earning Date
- WCT 05-16-2025
- HOOK 08-07-2025
- Dividend Yield
- WCT N/A
- HOOK N/A
- EPS Growth
- WCT N/A
- HOOK N/A
- EPS
- WCT N/A
- HOOK N/A
- Revenue
- WCT $2,309,218.00
- HOOK $9,351,000.00
- Revenue This Year
- WCT N/A
- HOOK N/A
- Revenue Next Year
- WCT N/A
- HOOK N/A
- P/E Ratio
- WCT N/A
- HOOK N/A
- Revenue Growth
- WCT N/A
- HOOK N/A
- 52 Week Low
- WCT $0.12
- HOOK $0.72
- 52 Week High
- WCT $9.36
- HOOK $6.77
- Technical
- Relative Strength Index (RSI)
- WCT N/A
- HOOK 38.94
- Support Level
- WCT N/A
- HOOK $1.23
- Resistance Level
- WCT N/A
- HOOK $1.30
- Average True Range (ATR)
- WCT 0.00
- HOOK 0.06
- MACD
- WCT 0.00
- HOOK -0.03
- Stochastic Oscillator
- WCT 0.00
- HOOK 5.97
About WCT WELLCHANGE HOLDINGS COMPANY LIMITED
Wellchange Holdings Co Ltd is an enterprise software solution services provider. It provides software solutions, cloud-based software-as-a-service (SaaS) platforms, and white-label software design and development services.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.